# US 8,278,437 B2 · Hydroxypropyl-sulfobutyl-beta-cyclodextrin, the preparation method, the analytical method, and the pharmacutical application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,437 B2
- Document ID: US8278437B2
- Status: Granted
- Kind: B2
- Application number: 12/092,273
- Filed: 2005-11-28
- Published: 2009-01-08
- Granted: 2012-10-02
- Earliest claimed: 2005-11-02
- Assignees: Hainan Hdeton Science and Technology Co. Ltd.
- Inventors: Yong Ren; Xueqin Ma; Shuqin Yu; Xiaodong Sun
- Web page: https://patentgrep.com/patent/US8278437B2

## CPC

- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/724: Cyclodextrins
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C08B 37/0012: {Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof}
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- C08L 5/16: Cyclodextrin; Derivatives thereof
- G01N 2030/884: {organic compounds}
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin, the preparation method, analytical method, and the pharmaceutical application thereof. The hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin is a derivate of cyclodextrin which is substituted by hydroxypropyl group and sulfobutyl group: n-(2,3,6-O-2-hydroxypropyl)-m-(2,3,6-O-sulfobutyl)-&bgr;-cyclodextrin. The number of substituent groups per mole cyclodextrin is n hydroxypropyl groups and m sulfobutyl groups. “n” represents the average substituent degree of hydroxypropyl groups; “m” represents the average substituent degree of sulfobutyl groups; “n+m=z” is the gross average substituent degree, in which n is a random integer chosen from 1,2,3,4,5,6,7,8,9; m is a random integer chosen from 1,2,3,4,5,6,7,8,9; and the gross average substituent degree z is a random integer chosen from 2,3,4,5,6,7,8,9,10. The present invention shows low haemolysis and low toxicity.

## Claims

### Claim 1

A hydroxypropyl-sulfobutyl-β-cyclodextrin, wherein said hydroxypropyl -sulfobutyl-β-cyclodextrin is a cyclodextrin derivative mixed substituted by hydroxypropyl and sulfobutyl groups: n-(2,3,6-O-2-hydroxypropyl)-m-(2,3,6-O-sulfobutyl)-β-cyclodextrin, wherein said cyclodextrin derivative has the following structure denoted by the following general formula:

### Claim 2 (depends on 1)

The hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 1, wherein the number of substituent groups per mole cyclodextrin is n hydroxypropyl groups and m sulfobutyl groups; “n” represents the average degree of substitution of hydroxypropyl groups; “m” represents the average degree of substitution of sulfobutyl groups; “n+m=z” is the gross average degree of substitution, in which n is a random integer selected among 1,2,3,4,5,6,7,8,9; m is a random integer selected among 1,2,3,4,5,6,7,8,9; and the gross average degree of substitution z is a random integer selected among 2,3,4,5,6,7,8,9,10.

### Claim 3 (depends on 2)

The hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 2, wherein said hydroxypropyl-sulfobutyl-β-cyclodextrin is selected among:
HP2-SBE3-β-CD; Z = 5,
HP1-SBE4-β-CD; Z = 5,
HP3-SBE6-β-CD; Z = 9,
HP2-SBE2-β-CD; Z = 4,
HP3-SBE2-β-CD; Z = 5,
HP3-SBE4-β-CD; Z = 7,
HP4-SBE2-β-CD; Z = 6,
HP4-SBE3-β-CD; Z = 7,
HP5-SBE2-β-CD; Z = 7,
HP5-SBE3-β-CD; Z = 8,
HP6-SBE2-β-CD; Z = 8.

### Claim 4 (depends on 1, 2, 3)

The hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 1 or claim 2 or claim 3, wherein said hydroxypropyl-sulfobutyl-β-cyclodextrin is cyclodextrin derivative of X═Na, K, Li.

### Claim 5 (depends on 4)

The hydroxypropyl-sulfobutyl-β-cyclodextrin as claimed in claim 4, wherein said cyclodextrin derivative of X═Na, K, Li is selected among:
HP2-SBE3-β-CD
HP3-SBE4-β-CD
HP5-SBE3-β-CD
HP1-SBE4-β-CD
HP4-SBE2-β-CD
HP6-SBE2-β-CD
HP3-SBE6-β-CD
HP4-SBE3-β-CD
HP3-SBE2-β-CD
HP2-SBE2-β-CD
HP5-SBE2-β-CD.

### Claim 6 (depends on 5)

The hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 5, wherein said average degree of substitution of n and m also includes the actual average value ±0.5, the range of average degree of substitution is:
HP2-SBE3-β-CD
n = 1.5~2.4; m = 2.5~3.4
HP1-SBE4-β-CD
n = 1.0~1.4; m = 3.5~4.4
HP3-SBE6-β-CD
n = 2.5~3.4; m = 5.5~6.4
HP2-SBE2-β-CD
n = 1.5~2.4; m = 1.5~2.4
HP3-SBE4-β-CD
n = 2.5~3.4; m = 3.5~4.4
HP4-SBE2-β-CD
n = 3.5~4.4; m = 1.5~2.4
HP4-SBE3-β-CD
n = 3.5~4.4; m = 2.5~3.4
HP5-SBE2-β-CD
n = 4.5~5.4; m = 1.5~2.4
HP5-SBE3-β-CD
n = 4.5~5.4; m = 2.5~3.4
HP6-SBE2-β-CD
n = 5.5~6.4; m = 1.5~2.4
HP3-SBE2-β-CD
n = 2.5~3.4; m = 1.5~2.4.

### Claim 7 (depends on 5, 6)

The hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 5 or claim 6, wherein the content of unmodified cyclodextrin is not more than 1.5%.

### Claim 8 (depends on 1)

The preparation method of said hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 1, the method comprising:
combining 2-4 times of water by weight and 2-17 molar equivalents of base to cyclodextrin;
slowly adding a first and second reagent selected from 2-15 molar equivalents of 1,4-butyl sultone and 1.5-13 molar equivalents of 1,2-propylene oxide to the cyclodextrin solution, wherein either reagent may be the first reagent, and the first reagent is allowed to react for 5-8 h before addition of the second reagent that reacts for an additional 5-8 h;
adding a supplemental 2-15 molar equivalents of base after 1,2-propylene oxide has reacted when 1,2-propylene oxide is added first; and
wherein 1,4-butyl sultone reacts at 80° C., and 1,2-propylene oxide reacts at room temperature to produce a crude product of hydroxypropyl-sulfobutyl-β-cyclodextrin that is neutralized to a pH of 6-7 with hydrochloric acid, and filtered, further wherein the filtrate is dialyzed and dried under the condensation and pressure reduction condition to obtain the product.

### Claim 9 (depends on 8)

The preparation method of said hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 8, wherein the specific steps can be one of the following two options:
the cyclodextrin is added with 2-4 times of water by weight and 2 molar equivalents of base, stirred at room temperature then reacted with 1.5-13 molar equivalents of 1,2-propylene oxide, and reacted for 7-8 hours, then 2-15 molar equivalents of base is added, heated to 80° C., then reacted with 2-15 molar equivalents of 1,4-butyl sultone for 5-8 hours, to produce hydroxypropyl-sulfobutyl-β-cyclodextrin product of specific degree of substitution;
or the cyclodextrin is added with 2-4 times of water by weight and 3-17 molar equivalents of base, stirred and heated to 80° C., then reacted with 2-15 molar equivalents of 1,4-butyl sultone for 5-8 hours, cooled down to room temperature, then under the controlled room temperature, reacted with 1.5-13 molar equivalents of 1,2-propylene oxide for 7-8 hours, to produce hydroxypropyl -sulfobutyl-β-cyclodextrin product of specific degree of substitution.

### Claim 10 (depends on 8)

The preparation method of said hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 8, wherein unmodified cyclodextrin is used as raw material, and mixed substitution of continuous feeding reaction steps without separation of reaction intermediate is adopted.

### Claim 11 (depends on 1)

The analytic method of said hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 1, wherein hydroxypropyl-sulfobutyl-β-cyclodextrin product is dissolved by water, or methanol ,or ethanol, or acetonitrile, or methanol-water, or ethanol-water, or acetonitrile-water solution, or two or three of solutions thereof, the product is analyzed by chromatography with sample solution.

### Claim 12 (depends on 11)

The analytic method of said hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 11, wherein said analytic method is to analyze the product content or purity by High-Performance Liquid Chromatography.

### Claim 13 (depends on 11)

The analytic method of said hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 11, wherein said analytic method is to analyze the organic impurities of the product by gas chromatography.

### Claim 14 (depends on 1)

The hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 1, wherein said hydroxypropyl-sulfobutyl-β-cyclodextrin is used for preparation of combination for medical purpose by inclusion or mixture with active molecule as excipients.

### Claim 15 (depends on 14)

The pharmaceutical application of hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 14, wherein said hydroxypropyl-sulfobutyl-β-cyclodextrin combination is used as oral preparations for treatment or health care purpose.

### Claim 16 (depends on 14)

The pharmaceutical application of hydroxypropyl-sulfobutyl-β-cyclodextrin of claim 14, wherein said hydroxypropyl-sulfobutyl-β-cyclodextrin combination is used as non-oral preparations for treatment or health care purpose.
